Business
ACCRUFeR® Approved by Health Canada
ACCRUFeR® Approved by Health Canada.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n\n Shield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \nACCRUFeR® Approved by Health Canada\n \nACCRUFeR® is the only oral iron therapy approved as a prescription drug in Canada\n \n \nLondon, UK, 27 August 2024: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anaemia), today announces that Health Canada has approved ACCRUFeR® (ferric maltol) as a prescription drug for the treatment of adults with iron deficiency anemia (IDA). This development allows Shield's partner, Kye Pharmaceuticals Inc. (Kye), to launch ACCRUFeR® in Canada. Shield will be responsible for all manufacturing and supply to the Canadian market.\n \nIn accordance with the collaborative agreement, Shield is now due to receive a £250,000 milestone payment. For the remaining term of the agreement, Shield will receive additional revenue-based milestone payments along with double-digit royalties on net sales of ACCRUFeR®. \n \nAnders Lundstrom, Interim CEO of Shield, commented: \"We are delighted with the progress made in partnership with Kye since the signing of the license agreement in January 2022. Both organisations have demonstrated excellent collaboration and are driven to make ACCRUFeR® available to patients in Canada with iron deficiency as quickly as possible. Shield Therapeutics is committed to bringing ACCRUFeR®/FeRACCRU® to patients with iron deficiency around the world, and Canada is an important component of that mission.\"\n \nJohn McKendry, President and CEO of Kye, commented: \"ACCRUFeR® will be the only prescription oral therapy available in Canada to treat patients who continue to suffer from low iron despite attempts at treatment with other currently available options. Our partnership with Shield and the granting of marketing authorization for ACCRUFeR® in Canada grant us the opportunity to bring a novel, high-quality therapeutic option to patients in Canada who are struggling to address mild to moderate iron deficiency or iron deficiency anemia.\"\n \nFor further information please contact:\n \n\n\n\n\nShield...